Skip to main content
Premium Trial:

Request an Annual Quote

Canadian Hospital Using PerkinElmer Tools for Newborn Screening Program

NEW YORK (GenomeWeb News) — Capital Health of Alberta is using PerkinElmer’s mass spectrometers, reagents, and software in a newborn screening program, PerkinElmer said today.

Under a multi-year agreement, the Edmonton-based Capital Health has bought PerkinElmer’s tandem mass spectrometry systems, reagent kits, and its Specimen Gate software to screen newborns for 17 hereditary metabolic disorders, including cystic fibrosis.  

PerkinElmer said the program will cover the entire province, and makes Alberta the first in Canada to screen all newborns for cystic fibrosis, the company said.  

Financial terms of the agreement were not released.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.